Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial for Dose Escalation and Safety Assessment and Clinical Response of Anti-SARS-CoV-2 Serum Produced by Instituto Butantan

NCT04834089 is registered in ClinicalTrials.gov with Butantan Institute as lead sponsor.

NCT NCT04834089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04834089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial for Dose Escalation and Safety Assessment and Clinical Response of Anti-SARS-CoV-2 Serum Produced by Instituto Butantan
Lead sponsor
Butantan Institute
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2021
Completion date
May 31, 2022
Enrollment
618 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cardiovascular diseases, chemotherapy, chronic obstructive pulmonary disease, covid-19, diabetes mellitus, immunosuppression, other complication of kidney transplant, renal disease